API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 6 sources · 14 days · First seen · Last updated

Polish pharmaceutical market regulatory changes

Overview

The Polish pharmaceutical sector is undergoing significant structural and legislative transformations. Initially, the market faced intense regulatory enforcement, with the Office of Competition and Consumer Protection (UOKiK) imposing over 900 million PLN in fines on major wholesalers, such as Farmacol, Neuca, and Świat Zdrowia, for involvement in unlawful agreements.

Legislative shifts have also focused on drug accessibility and marketing. Following a June 2025 ruling by the Court of Justice of the European Union, Poland is set to lift a long-standing ban on pharmacy advertising effective December 3, 2026. While pharmacies may now promote services like vaccinations and diagnostic tests through digital and traditional media, strict prohibitions remain. These include bans on comparative advertising, offering discounts, and using the likeness of celebrities or medical professionals. Non-compliance with these new marketing rules carries heavy financial risks, with potential fines reaching 1 million PLN per violation.

Entities

Poland · Farmacol · Office of Competition and Consumer Protection · Karol Nawrocki · Neuca

Timeline

  1. [BUSINESS] 6 sources
    Poland to allow pharmacy advertising starting December 3

    Poland will lift its 14-year ban on pharmacy advertising on December 3, 2026, following an EU court ruling, though strict rules on discounts and celebrity endorsements will remain.

  2. [BUSINESS] 4 sources
    Poland pharmacy market faces regulatory shifts and heavy fines

    Poland's pharmacy market is facing major shifts due to massive antitrust fines against wholesalers and new laws lifting advertising bans while introducing strict, per-point penalties.

Sources

dziennik.pl · fakt.pl · mzdrowie.pl · podatki.gazetaprawna.pl · rynekzdrowia.pl · zdrowie.co.pl